Summary

This article presents results from the Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion trial [X-VeRT; Cappato R et al. Eur Heart J. 2014]. The data showed that oral rivaroxaban was as effective and safe as a vitamin K antagonist when administered for only about a week prior to elective cardioversion for atrial fibrillation.